Acute Treatment of Stroke (Except Thrombectomy)

  • Paula Muñoz Venturelli
  • Jason P. Appleton
  • Craig S. AndersonEmail author
  • Philip M. Bath
Stroke (H Diener, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Stroke


Purpose of Review

The management of patients with acute stroke has been revolutionized in recent years with the advent of new effective treatments. In this rapidly evolving field, we provide an update on the management of acute stroke excluding thrombectomy, looking to recent, ongoing, and future trials.

Recent Findings

Large definitive trials have provided insight into acute stroke care including broadening the therapeutic window for thrombolysis, alternatives to standard dose alteplase, the use of dual antiplatelet therapy early after minor ischemic stroke, and treating elevated blood pressure in intracerebral hemorrhage. Further ongoing and future trials are eagerly awaited in this ever-expanding area.


Although definitive trials have led to improvements in acute stroke care, there remains a need for further research to improve our understanding of pathophysiological mechanisms underlying different stroke types with the potential for treatments to be tailored to the individual.


Acute ischemic stroke Intracerebral hemorrhage Thrombolysis Antiplatelets Blood pressure Stroke unit 


Compliance with Ethical Standards

Conflict of Interest

Dr. Anderson reports grants from the National Health and Medical Research Council (NHMRC) of Australia, personal fees from Amgen, grants from Takeda China, and personal fees from Takeda China, outside the submitted work. Dr. Bath reports personal fees from Nestle, non-financial support and other from Platelet Solutions, personal fees and other from DiaMedica, and personal fees from Phagenesis, outside the submitted work. Dr. Muñoz Venturelli reports grants from FONDECYT Regular 2018, grants from Clínica Alemana de Santiago, and grants from The George Institute for Global Health, during the conduct of the study.

Dr. Appleton declares no potential conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Mackay J, Mensah G. The atlas of heart disease and stroke. WHO library 2004. Available from: http://www.Who.Int/cardiovascular_diseases/resources/atlas/en/.
  2. 2.
    Lees KR, Emberson J, Blackwell L, Bluhmki E, Davis SM, Donnan GA, et al. Effects of alteplase for acute stroke on the distribution of functional outcomes: a pooled analysis of 9 trials. Stroke. 2016;47:2373–9.CrossRefGoogle Scholar
  3. 3.
    Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–29.CrossRefGoogle Scholar
  4. 4.
    Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017–25.CrossRefGoogle Scholar
  5. 5.
    Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (sits-most): an observational study. Lancet. 2007;369:275–82.CrossRefGoogle Scholar
  6. 6.
    Sheinberg DL, McCarthy DJ, Peterson EC, Starke RM. Defuse-3 trial: reinforcing evidence for extended endovascular intervention time window for ischemic stroke. World Neurosurg. 2018;112:275–6.CrossRefGoogle Scholar
  7. 7.
    Fink JN, Kumar S, Horkan C, Linfante I, Selim MH, Caplan LR, et al. The stroke patient who woke up: clinical and radiological features, including diffusion and perfusion MRI. Stroke. 2002;33:988–93.CrossRefGoogle Scholar
  8. 8.
    Thomalla G, Cheng B, Ebinger M, Hao Q, Tourdias T, Wu O, et al. DWI-flair mismatch for the identification of patients with acute ischaemic stroke within 4.5 h of symptom onset (pre-flair): a multicentre observational study. Lancet Neurol. 2011;10:978–86.CrossRefGoogle Scholar
  9. 9.
    Wintermark M, Flanders AE, Velthuis B, Meuli R, van Leeuwen M, Goldsher D, et al. Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke. 2006;37:979–85.CrossRefGoogle Scholar
  10. 10.
    Bivard A, Levi C, Spratt N, Parsons M. Perfusion CT in acute stroke: a comprehensive analysis of infarct and penumbra. Radiology. 2013;267:543–50.CrossRefGoogle Scholar
  11. 11.
    Campbell BC, Christensen S, Levi CR, Desmond PM, Donnan GA, Davis SM, et al. Comparison of computed tomography perfusion and magnetic resonance imaging perfusion-diffusion mismatch in ischemic stroke. Stroke. 2012;43:2648–53.CrossRefGoogle Scholar
  12. 12.
    Dani KA, Thomas RG, Chappell FM, Shuler K, MacLeod MJ, Muir KW, et al. Computed tomography and magnetic resonance perfusion imaging in ischemic stroke: definitions and thresholds. Ann Neurol. 2011;70:384–401.CrossRefGoogle Scholar
  13. 13.
    Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018;378:708–18.CrossRefGoogle Scholar
  14. 14.
    •• Thomalla G, Simonsen CZ, Boutitie F, Andersen G, Berthezene Y, Cheng B, et al. MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med. 2018. WAKE-UP trial: Alteplase vs. normal saline in those with stroke of unknown time of onset with MRI diffusion-FLAIR mismatch was associated with improved 90 day functional outcome. Google Scholar
  15. 15.
    Kim BJ, Han MK, Park TH, Park SS, Lee KB, Lee BC, et al. Low-versus standard-dose alteplase for ischemic strokes within 4.5 hours: a comparative effectiveness and safety study. Stroke. 2015;46:2541–8.CrossRefGoogle Scholar
  16. 16.
    • Anderson CS, Robinson T, Lindley RI, Arima H, Lavados PM, Lee TH, et al. Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke. N Engl J Med. 2016;374:2313–23. ENCHANTED trial: low-dose vs. standard-dose alteplase failed to show non-inferiority, but those on antiplatelet agents pre-stroke may benefit from low-dose. CrossRefGoogle Scholar
  17. 17.
    Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49:e46–e110.CrossRefGoogle Scholar
  18. 18.
    Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by mri perfusion-diffusion weighted imaging or perfusion ct (dias-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2009;8:141–50.CrossRefGoogle Scholar
  19. 19.
    Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, et al. The desmoteplase in acute ischemic stroke trial (dias): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36:66–73.CrossRefGoogle Scholar
  20. 20.
    von Kummer R, Mori E, Truelsen T, Jensen JS, Gronning BA, Fiebach JB, et al. Desmoteplase 3 to 9 hours after major artery occlusion stroke: the DIAS-4 trial (efficacy and safety study of desmoteplase to treat acute ischemic stroke). Stroke. 2016;47:2880–7.CrossRefGoogle Scholar
  21. 21.
    Huang X, Cheripelli BK, Lloyd SM, Kalladka D, Moreton FC, Siddiqui A, et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (attest): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol. 2015;14:368–76.CrossRefGoogle Scholar
  22. 22.
    Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366:1099–107.CrossRefGoogle Scholar
  23. 23.
    Logallo N, Novotny V, Assmus J, Kvistad CE, Alteheld L, Ronning OM, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (nor-test): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017;16:781–8.CrossRefGoogle Scholar
  24. 24.
    •• Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med. 2018;378:1573–82. EXTEND-IA TNK trial: TNK vs. alteplase in large vessel occlusion pre-thrombectomy. TNK reduced the need for thrombectomy and improved 90 day functional outcome without increasing sICH. CrossRefGoogle Scholar
  25. 25.
    Ciccone A, Motto C, Abraha I, Cozzolino F, Santilli I. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke. Cochrane Database Syst Rev. 2014;204(3):CD005208.Google Scholar
  26. 26.
    Abciximab Emergent Stroke Treatment Trial I. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke. 2005;36:880–90.CrossRefGoogle Scholar
  27. 27.
    Adeoye O, Sucharew H, Khoury J, Tomsick T, Khatri P, Palesch Y, et al. Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis. Stroke. 2015;46:461–4.CrossRefGoogle Scholar
  28. 28.
    Adeoye O, Sucharew H, Khoury J, Vagal A, Schmit PA, Ewing I, et al. Combined approach to lysis utilizing eptifibatide and recombinant tissue-type plasminogen activator in acute ischemic stroke-full dose regimen stroke trial. Stroke. 2015;46:2529–33.CrossRefGoogle Scholar
  29. 29.
    Langhorne P, O'Donnell MJ, Chin SL, Zhang H, Xavier D, Avezum A, et al. Practice patterns and outcomes after stroke across countries at different economic levels (interstroke): an international observational study. Lancet. 2018;391:2019–27.CrossRefGoogle Scholar
  30. 30.
    Stroke Unit Trialists C. Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev. 2013;9:CD000197.Google Scholar
  31. 31.
    Schwamm LH, Fonarow GC, Reeves MJ, Pan W, Frankel MR, Smith EE, et al. Get with the guidelines-stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation. 2009;119:107–15.CrossRefGoogle Scholar
  32. 32.
    Munoz Venturelli P, Robinson T, Lavados PM, Olavarria VV, Arima H, Billot L, et al. Regional variation in acute stroke care organisation. J Neurol Sci. 2016;371:126–30.CrossRefGoogle Scholar
  33. 33.
    Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013;309:2480–8.CrossRefGoogle Scholar
  34. 34.
    Krebs W, Sharkey-Toppen TP, Cheek F, Cortez E, Larrimore A, Keseg D, et al. Prehospital stroke assessment for large vessel occlusions: a systematic review. Prehosp Emerg Care. 2018;22:180–8.CrossRefGoogle Scholar
  35. 35.
    Fonarow GC, Smith EE, Saver JL, Reeves MJ, Hernandez AF, Peterson ED, et al. Improving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association's target: stroke initiative. Stroke. 2011;42:2983–9.CrossRefGoogle Scholar
  36. 36.
    Meretoja A, Strbian D, Mustanoja S, Tatlisumak T, Lindsberg PJ, Kaste M. Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology. 2012;79:306–13.CrossRefGoogle Scholar
  37. 37.
    Meretoja A, Weir L, Ugalde M, Yassi N, Yan B, Hand P, et al. Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months. Neurology. 2013;81:1071–6.CrossRefGoogle Scholar
  38. 38.
    Wu TY, Coleman E, Wright SL, Mason DF, Reimers J, Duncan R, et al. Helsinki stroke model is transferrable with “real-world” resources and reduced stroke thrombolysis delay to 34 min in Christchurch. Front Neurol. 2018;9:290.CrossRefGoogle Scholar
  39. 39.
    Akbik F, Hirsch JA, Chandra RV, Frei D, Patel AB, Rabinov JD, et al. Telestroke-the promise and the challenge. Part one: growth and current practice. J Neurointerv Surg. 2017;9:357–60.CrossRefGoogle Scholar
  40. 40.
    Kepplinger J, Barlinn K, Deckert S, Scheibe M, Bodechtel U, Schmitt J. Safety and efficacy of thrombolysis in telestroke: a systematic review and meta-analysis. Neurology. 2016;87:1344–51.CrossRefGoogle Scholar
  41. 41.
    Rothwell PM, Giles MF, Chandratheva A, Marquardt L, Geraghty O, Redgrave JN, et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (express study): a prospective population-based sequential comparison. Lancet. 2007;370:1432–42.CrossRefGoogle Scholar
  42. 42.
    International Stroke Trial Collaborative Group. The international stroke trial (ist); a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet. 1997;349:1569–81.CrossRefGoogle Scholar
  43. 43.
    CAST (Chinese Acute Stroke Trial) Collaborative Group. Cast: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet. 1997;349:1641–9.CrossRefGoogle Scholar
  44. 44.
    Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369:11–9.CrossRefGoogle Scholar
  45. 45.
    Wong KS, Wang Y, Leng X, Mao C, Tang J, Bath PM, et al. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis. Circulation. 2013;128:1656–66.CrossRefGoogle Scholar
  46. 46.
    •• Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk tia. N Engl J Med. 2018;379:215–25. POINT trial: aspirin and clopidogrel vs. aspirin within 12 hours of minor stroke or TIA was associated with reduced major ischemic events but increased major bleeding at 90 days. CrossRefGoogle Scholar
  47. 47.
    Johnston S, Amarenco P, Alberts G, Denison H, Easton J, Evans S, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375:35–43.CrossRefGoogle Scholar
  48. 48.
    Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, et al. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of socrates, a randomised, double-blind, controlled trial. Lancet Neurol. 2017;16:301–10.CrossRefGoogle Scholar
  49. 49.
    • Bath PM, Woodhouse LJ, Appleton JP, Beridze M, Christensen H, Dineen RA, et al. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (tardis): a randomised, open-label, phase 3 superiority trial. Lancet. 2018;391:850–9. TARDIS trial: triple antiplatelet therapy vs. guideline therapy with 24 hours of AIS or TIA did not reduce stroke recurrence but did cause more, and more severe bleeding. CrossRefGoogle Scholar
  50. 50.
    Munoz Venturelli P, Olavarria V, Gonzalez F, Brunser A, Lavados P, Arima H, et al. Head position in the early phase of acute ischemic stroke: an international survey of current practice. J Stroke Cerebrovasc Dis. 2015;24:1564–9.CrossRefGoogle Scholar
  51. 51.
    Olavarría VV, Arima H, Anderson CS, Brunser AM, Muñoz-Venturelli P, Heritier S, et al. Head position and cerebral blood flow velocity in acute ischemic stroke: a systematic review and meta-analysis. Cerebrovasc Dis. 2014;37:401–8.CrossRefGoogle Scholar
  52. 52.
    Brunser AM, Muñoz Venturelli P, Lavados PM, Gaete J, Martins S, Arima H, et al. Head position and cerebral blood flow in acute ischemic stroke patients: protocol for the pilot phase, cluster randomized, head position in acute ischemic stroke trial (headpost pilot). Int J Stroke. 2016;11:253–9.CrossRefGoogle Scholar
  53. 53.
    Olavarría VV, Brunser A, Munoz Venturelli P, Arima H, Gonzalez F, Gaete J, et al. Head position in stroke trial (headpost) pilot phase results. Euro Stroke J. 2016;1:3–612.Google Scholar
  54. 54.
    • Anderson CS, Arima H, Lavados P, Billot L, Hackett ML, Olavarría VV, et al. Cluster-randomized, crossover trial of head positioning in acute stroke. N Engl J Med. 2017;376:2437–47. HEADPOST trial: lying flat vs. elevated head positioning in acute stroke did not influence 90 day functional outcome. CrossRefGoogle Scholar
  55. 55.
    Muñoz-Venturelli P, Arima H, Lavados P, Brunser A, Peng B, Cui L, et al. Head position in stroke trial (headpost) – sitting-up vs lying-flat positioning of patients with acute stroke: study protocol for a cluster randomised controlled trial. Trials. 2015;16:256.CrossRefGoogle Scholar
  56. 56.
    Britton M, Carlsson A, de Faire U. Blood pressure course in patients with acute stroke and matched controls. Stroke. 1986;17:861–4.CrossRefGoogle Scholar
  57. 57.
    Sprigg N, Gray LJ, Bath PMW, Boysen G, De Deyn PP, Friis P, et al. Relationship between outcome and baseline blood pressure and other haemodynamic mreasures in acute ischaemic stroke: data from the TAIST trial. J Hypertension. 2006;24:1413–7.CrossRefGoogle Scholar
  58. 58.
    Ohwaki K, Yano E, Nagashima H, Hirata M, Nakagomi T, Tamura A. Blood pressure management in acute intracerebral hemorrhage - relationship between elevated blood pressure and hematoma enlargement. Stroke. 2004;35:1364–7.CrossRefGoogle Scholar
  59. 59.
    Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke. 2002;33:1315–20.CrossRefGoogle Scholar
  60. 60.
    Willmot M, Leonardi-Bee J, Bath PM. High blood pressure in acute stroke and subsequent outcome: a systematic review. Hypertension. 2004;43:18–24.CrossRefGoogle Scholar
  61. 61.
    Bath PM, Appleton JP, Krishnan K, Sprigg N. Blood pressure in acute stroke: to treat or not to treat: that is still the question. Stroke. 2018;49:1784–90.CrossRefGoogle Scholar
  62. 62.
    Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368:2355–65.CrossRefGoogle Scholar
  63. 63.
    •• Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016;375:1033–43. ATACH-II trial: intensive vs. standard BP lowering within 4.5hrs of ICH onset did not influence functional outcome at 90 days for reasons discussed above. CrossRefGoogle Scholar
  64. 64.
    Steiner T, Al-Shahi Salman R, Beer R, Christensen H, Cordonnier C, Csiba L, et al. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke. 2014;9:840–55.CrossRefGoogle Scholar
  65. 65.
    Hemphill J, Greenberg S, Anderson C, Becker K, Bendok B, Cushman M, et al. Guidelines for the management of spontaneous intracerebral hemorrhage. Stroke. 2015;46:2032–2060. Early online.CrossRefGoogle Scholar
  66. 66.
    Royal College of Physicians. National clinical guideline for stroke. Prepared by the intercollegiate stroke working party. 2016.Google Scholar
  67. 67.
    Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension. 2018;71:1269–324.CrossRefGoogle Scholar
  68. 68.
    Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, et al. Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol. 2017;33:557–76.CrossRefGoogle Scholar
  69. 69.
    Huang Y, Sharma V, Robinson T, Lindley R, Chen X, Kim J, et al. Rationale, design, and progress of the enhanced control of hypertension andthrombolysis stroke study (enchanted) trial: an international multicenter 2 × 2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-pa andearly intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment. Int J Stroke. 2015;10:778–88.CrossRefGoogle Scholar
  70. 70.
    Bath PM, Krishnan K. Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database Syst Rev. 2014;10:CD000039.pub3. Scholar
  71. 71.
    Woodhouse L, Scutt P, Krishnan K, Berge E, Gommans J, Ntaios G, et al. Effect of hyperacute administration (within 6 hours) of transdermal glyceryl trinitrate, a nitric oxide donor, on outcome after stroke: subgroup analysis of the efficacy of nitric oxide in stroke (ENOS) trial. Stroke. 2015;46:3194–201.CrossRefGoogle Scholar
  72. 72.
    Ankolekar S, Fuller M, Cross I, Renton C, Cox P, Sprigg N, et al. Feasibility of an ambulance-based stroke trial, and safety of glyceryl trinitrate in ultra-acute stroke: the rapid intervention with glyceryl trinitrate in hypertensive stroke trial (right, isrctn66434824). Stroke. 2013;44:3120–8.CrossRefGoogle Scholar
  73. 73.
    Appleton JP, Scutt P, Dixon M, Howard H, Haywood L, Havard D, et al. Ambulance-delivered transdermal glyceryl trinitrate versus sham for ultra-acute stroke: rationale, design and protocol for the rapid intervention with glyceryl trinitrate in hypertensive stroke trial-2 (RIGHT-2) trial (isrctn26986053). Int J Stroke 2017;0:1–16. 1747493017724627.Google Scholar
  74. 74.
    Ferdinand P, Roffe C. Hypoxia after stroke: a review of experimental and clinical evidence. Exp Transl Stroke Med. 2016;8:9.CrossRefGoogle Scholar
  75. 75.
    Rocco A, Pasquini M, Cecconi E, Sirimarco G, Ricciardi MC, Vicenzini E, et al. Monitoring after the acute stage of stroke: a prospective study. Stroke. 2007;38:1225–8.CrossRefGoogle Scholar
  76. 76.
    Rowat AM, Dennis MS, Wardlaw JM. Hypoxaemia in acute stroke is frequent and worsens outcome. Cerebrovasc Dis. 2006;21:166–72.CrossRefGoogle Scholar
  77. 77.
    • Roffe C, Nevatte T, Sim J, Bishop J, Ives N, Ferdinand P, et al. Effect of routine low-dose oxygen supplementation on death and disability in adults with acute stroke: the stroke oxygen study randomized clinical trial. JAMA. 2017;318:1125–35. SOS trial: three days of prophylactic low-dose oxygen therapy did not influence functional outcome at 90 days. CrossRefGoogle Scholar
  78. 78.
    Stroke Alliance for Europe. Proof trial. 2018;2018. (accessed 15 August 2018).
  79. 79.
    Gray CS, Hildreth AJ, Sandercock PA, O'Connell JE, Johnston DE, Cartlidge NE, et al. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol. 2007;6:397–406.CrossRefGoogle Scholar
  80. 80.
    Bereczki D, Liu M, Fernandes do Prado G, Fekete I. Mannitol for acute stroke. Cochrane Database Syst Rev. 2007. 2007;(3):CD001153Google Scholar
  81. 81.
    Wang X, Arima H, Yang J, Zhang SH, Wu GJ, Woodward M, et al. Mannitol and outcome in intracerebral hemorrhage propensity score and multivariable intensive blood pressure reduction in acute cerebral hemorrhage trial 2 results. Stroke. 2015;46:2762–7.CrossRefGoogle Scholar
  82. 82.
    Sheth KN, Elm JJ, Molyneaux BJ, Hinson H, Beslow LA, Sze GK, et al. Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2016;15:1160–9.CrossRefGoogle Scholar
  83. 83.
    Sandercock PAG, Counsell C, Kane EJ. Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev. 2015;(3):CD000024Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Paula Muñoz Venturelli
    • 1
    • 2
    • 3
  • Jason P. Appleton
    • 4
    • 5
  • Craig S. Anderson
    • 1
    • 3
    • 6
    Email author
  • Philip M. Bath
    • 4
    • 5
  1. 1.Clinical Research Center, Instituto de Ciencias e Innovación en Medicina, Facultad de MedicinaClínica Alemana Universidad del DesarrolloSantiagoChile
  2. 2.Department of Neurology and PsychiatryClínica Alemana de SantiagoSantiagoChile
  3. 3.The George Institute for Global HealthUniversity of New South WalesSydneyAustralia
  4. 4.Stroke Trials Unit, Division of Clinical NeurosciencesUniversity of NottinghamNottinghamUK
  5. 5.Stroke, Nottingham University Hospitals NHS TrustNottinghamUK
  6. 6.The George Institute China at Peking University Health Science CenterBeijingChina

Personalised recommendations